213 related articles for article (PubMed ID: 17229606)
1. Xenovaccinotherapy for melanoma.
Seledtsov VI; Shishkov AA; Surovtseva MA; Samarin DM; Seledtsova GV; Niza NA; Seledtsov DV
Eur J Dermatol; 2006; 16(6):655-61. PubMed ID: 17229606
[TBL] [Abstract][Full Text] [Related]
2. Xenovaccinotherapy for colorectal cancer.
Seledtsov VI; Niza NA; Felde MA; Shishkov AA; Samarin DM; Seledtsova GV; Seledtsov DV
Biomed Pharmacother; 2007; 61(2-3):125-30. PubMed ID: 17258887
[TBL] [Abstract][Full Text] [Related]
3. Xenogeneic cell-based vaccine therapy for stage III melanoma: safety, immune-mediated responses and survival benefits.
Seledtsova GV; Shishkov AA; Kaschenko EA; Goncharov AG; Gazatova ND; Seledtsov VI
Eur J Dermatol; 2016 Apr; 26(2):138-43. PubMed ID: 27026566
[TBL] [Abstract][Full Text] [Related]
4. Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses.
Wei Y; Sticca RP; Holmes LM; Burgin KE; Li J; Williamson J; Evans L; Smith SJ; Stephenson JJ; Wagner TE
Int J Oncol; 2006 Mar; 28(3):585-93. PubMed ID: 16465362
[TBL] [Abstract][Full Text] [Related]
5. Xenogeneic cell-based vaccine therapy for colorectal cancer: Safety, association of clinical effects with vaccine-induced immune responses.
Seledtsova GV; Shishkov AA; Kaschenko EA; Seledtsov VI
Biomed Pharmacother; 2016 Oct; 83():1247-1252. PubMed ID: 27565847
[TBL] [Abstract][Full Text] [Related]
6. Prolonged survival of dendritic cell-vaccinated melanoma patients correlates with tumor-specific delayed type IV hypersensitivity response and reduction of tumor growth factor beta-expressing T cells.
López MN; Pereda C; Segal G; Muñoz L; Aguilera R; González FE; Escobar A; Ginesta A; Reyes D; González R; Mendoza-Naranjo A; Larrondo M; Compán A; Ferrada C; Salazar-Onfray F
J Clin Oncol; 2009 Feb; 27(6):945-52. PubMed ID: 19139436
[TBL] [Abstract][Full Text] [Related]
7. Active immunotherapy with ultraviolet B-irradiated autologous whole melanoma cells plus DETOX in patients with metastatic melanoma.
Eton O; Kharkevitch DD; Gianan MA; Ross MI; Itoh K; Pride MW; Donawho C; Buzaid AC; Mansfield PF; Lee JE; Legha SS; Plager C; Papadopoulos NE; Bedikian AY; Benjamin RS; Balch CM
Clin Cancer Res; 1998 Mar; 4(3):619-27. PubMed ID: 9533529
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic cells vaccine increases disease-free survival in stage III melanoma patients. A non randomized phase II study.
Mordoh J; Kairiyama C; Bover L; Solarolo E
Medicina (B Aires); 1997; 57(4):421-7. PubMed ID: 9674264
[TBL] [Abstract][Full Text] [Related]
9. Immunologic and clinical effects of injecting mature peptide-loaded dendritic cells by intralymphatic and intranodal routes in metastatic melanoma patients.
Lesimple T; Neidhard EM; Vignard V; Lefeuvre C; Adamski H; Labarrière N; Carsin A; Monnier D; Collet B; Clapisson G; Birebent B; Philip I; Toujas L; Chokri M; Quillien V
Clin Cancer Res; 2006 Dec; 12(24):7380-8. PubMed ID: 17189411
[TBL] [Abstract][Full Text] [Related]
10. Immunohistological analysis of peptide-induced delayed-type hypersensitivity in advanced melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination.
Nakai N; Katoh N; Germeraad WT; Kishida T; Ueda E; Takenaka H; Mazda O; Kishimoto S
J Dermatol Sci; 2009 Jan; 53(1):40-7. PubMed ID: 18804963
[TBL] [Abstract][Full Text] [Related]
11. Double-blind trial of a polyvalent, shed-antigen, melanoma vaccine.
Bystryn JC; Zeleniuch-Jacquotte A; Oratz R; Shapiro RL; Harris MN; Roses DF
Clin Cancer Res; 2001 Jul; 7(7):1882-7. PubMed ID: 11448900
[TBL] [Abstract][Full Text] [Related]
12. Dendritic cell-based vaccine in advanced melanoma: update of clinical outcome.
Ridolfi L; Petrini M; Fiammenghi L; Granato AM; Ancarani V; Pancisi E; Brolli C; Selva M; Scarpi E; Valmorri L; Nicoletti SV; Guidoboni M; Riccobon A; Ridolfi R
Melanoma Res; 2011 Dec; 21(6):524-9. PubMed ID: 21909041
[TBL] [Abstract][Full Text] [Related]
13. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
14. Immune response to postsurgical adjuvant active immunotherapy with Canvaxin polyvalent cancer vaccine: correlations with clinical course of patients with metastatic melanoma.
Morton DL
Dev Biol (Basel); 2004; 116():209-17; discussion 229-36. PubMed ID: 15603194
[TBL] [Abstract][Full Text] [Related]
15. Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence of systemic immune dysfunction.
; Celis E
Cancer; 2007 Jul; 110(1):203-14. PubMed ID: 17541944
[TBL] [Abstract][Full Text] [Related]
16. Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine.
Sondak VK; Sosman JA
Semin Cancer Biol; 2003 Dec; 13(6):409-15. PubMed ID: 15001159
[TBL] [Abstract][Full Text] [Related]
17. Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response.
Barth A; Hoon DS; Foshag LJ; Nizze JA; Famatiga E; Okun E; Morton DL
Cancer Res; 1994 Jul; 54(13):3342-5. PubMed ID: 8012946
[TBL] [Abstract][Full Text] [Related]
18. Lack of effect of cyclophosphamide on the immunogenicity of a melanoma antigen vaccine.
Oratz R; Dugan M; Roses DF; Harris MN; Speyer JL; Hochster H; Weissman J; Henn M; Bystryn JC
Cancer Res; 1991 Jul; 51(14):3643-7. PubMed ID: 2065322
[TBL] [Abstract][Full Text] [Related]
19. Expression of the apoptosis inhibitor protease inhibitor 9 predicts clinical outcome in vaccinated patients with stage III and IV melanoma.
van Houdt IS; Oudejans JJ; van den Eertwegh AJ; Baars A; Vos W; Bladergroen BA; Rimoldi D; Muris JJ; Hooijberg E; Gundy CM; Meijer CJ; Kummer JA
Clin Cancer Res; 2005 Sep; 11(17):6400-7. PubMed ID: 16144945
[TBL] [Abstract][Full Text] [Related]
20. Analysis and characterization of antitumor T-cell response after administration of dendritic cells loaded with allogeneic tumor lysate to metastatic melanoma patients.
Bercovici N; Haicheur N; Massicard S; Vernel-Pauillac F; Adotevi O; Landais D; Gorin I; Robert C; Prince HM; Grob JJ; Leccia MT; Lesimple T; Wijdenes J; Bartholeyns J; Fridman WH; Salcedo M; Ferries E; Tartour E
J Immunother; 2008 Jan; 31(1):101-12. PubMed ID: 18157017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
